7. Natera Inc. (NASDAQ:NTRA)
Natera, Inc. (NASDAQ: NTRA) ranks No. 7 among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and the company represents the diagnostics side of the modern healthcare investment story. Trading at $261.91, with the stock up 0.45%, Natera, Inc. (NASDAQ: NTRA) is backed by 68 hedge fund holders and remains one of the more closely followed genetic testing stocks, molecular diagnostics stocks, precision medicine stocks, and healthcare innovation stocks in the market. The company works in the discovery, development, and marketing of genetic testing services, giving it exposure to one of the most data-heavy corners of healthcare. As genetic testing becomes more common in oncology, reproductive health, transplant monitoring, and personalized medicine, companies like Natera, Inc. (NASDAQ: NTRA) are increasingly important to investors tracking the future of diagnostics.
On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx’s appeal in its false-advertising dispute with Natera, Inc. (NASDAQ: NTRA). The decision left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests. For Natera, Inc. (NASDAQ: NTRA), the outcome mattered because legal uncertainty can weigh on healthcare and diagnostics stocks, especially when disputes involve competing medical tests, marketing claims, and damages awards. Reuters said the justices declined to review whether Natera, Inc. (NASDAQ: NTRA) owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx’s AlloSure test. The Supreme Court offered no explanation for the decision, which is not unusual, but the practical result was that the lower-court outcome remained in place.
The case had a complicated history. Reuters noted that U.S. District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that Natera, Inc. (NASDAQ: NTRA)’s statements actually misled customers, although the jury’s finding of false advertising was still confirmed. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling. A Natera, Inc. (NASDAQ: NTRA) spokesperson said the company was pleased with the outcome. CareDx had argued that courts should presume deception when advertising is deliberately false, while Natera, Inc. (NASDAQ: NTRA) said the appellate court correctly applied the agreed trial instructions. For investors, the key takeaway is that Natera, Inc. (NASDAQ: NTRA) avoided the damages outcome that could have created a bigger financial and sentiment overhang.
The trivia behind Natera, Inc. (NASDAQ: NTRA)’s business is that diagnostics companies sit at the intersection of medicine, data, and clinical decision-making. Genetic testing creates large amounts of information that can help doctors better understand risk, disease progression, transplant status, and treatment decisions. As artificial intelligence and machine learning become more important in healthcare, diagnostic data may become even more valuable. AI-powered healthcare is not only about robots, hospital scheduling, or administrative automation. It is also about making sense of biological data, identifying patterns, improving test interpretation, and supporting personalized medicine. That is why diagnostics companies like Natera, Inc. (NASDAQ: NTRA) remain relevant in a broader conversation about AI-powered healthcare stocks.
Natera, Inc. (NASDAQ: NTRA) discovers, develops, and markets genetic testing services across multiple healthcare areas. For investors looking for precision medicine stocks, genetic testing stocks, diagnostic stocks, healthcare data stocks, and AI-related healthcare companies, Natera, Inc. (NASDAQ: NTRA) offers exposure to one of the most important long-term trends in medicine: using data to make healthcare more personalized and predictive. The legal update gives Natera, Inc. (NASDAQ: NTRA) a cleaner narrative, while its core diagnostics business keeps it tied to the future of genetic testing and data-driven healthcare.
Click next to see the following stock...
